A. Kate Sasser

Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma

Henk M. Lokhorst, Torben Plesner, Jacob P. Laubach et al. · New England Journal of Medicine · 2015 · 1.1K citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma

Jakub Krejcik, Tineke Casneuf, Inger S. Nijhof et al. · Blood · 2016 · 918 citations · Full text

Life Sciences, Immunology, Oncology +17

Mesenchymal Stem Cell Transition to Tumor-Associated Fibroblasts Contributes to Fibrovascular Network Expansion and Tumor Progression

Erika L. Spaeth, Jennifer L. Dembinski, A. Kate Sasser et al. · PLoS ONE · 2009 · 793 citations · Full text

Medicine, Cell Biology, Oncology +17

Interleukin-6 induces an epithelial–mesenchymal transition phenotype in human breast cancer cells

Nicholas J. Sullivan, A. Kate Sasser, Amy Axel et al. · Oncogene · 2009 · 755 citations

Medicine, Cell Biology, Oncology +16

Clinical efficacy of daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma

Saad Z. Usmani, Brendan M. Weiss, Torben Plesner et al. · Blood · 2016 · 404 citations · Full text

Medicine, Oncology, Pharmacotherapy +14